Lyra Therapeutics (LYRA) Competitors

$0.74 +0.09 (+13.62%)

As of 05/19/2026 03:00 PM Eastern

LYRA vs. ITOC, NXGL, BTCY, ZYXI, and SONX

Should you buy Lyra Therapeutics stock or one of its competitors? MarketBeat compares Lyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyra Therapeutics include Itonic (ITOC), NexGel (NXGL), Biotricity (BTCY), Zynex (ZYXI), and Sonendo (SONX). These companies are all part of the "medical equipment" industry.

How does Lyra Therapeutics compare to Itonic?

Lyra Therapeutics (NASDAQ:LYRA) and Itonic (NASDAQ:ITOC) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

95.6% of Lyra Therapeutics shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Itonic has lower revenue, but higher earnings than Lyra Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	2.18	-$93.43M	-$19.15	N/A
Itonic	$520K	9.66	-$5.10M	N/A	N/A

Itonic has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Itonic's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Itonic	N/A	N/A	N/A

In the previous week, Lyra Therapeutics' average media sentiment score of 0.00 equaled Itonic'saverage media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Itonic	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Itonic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lyra Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Itonic has a beta of 3.23, suggesting that its stock price is 223% more volatile than the broader market.

Summary

Itonic beats Lyra Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Lyra Therapeutics compare to NexGel?

NexGel (NASDAQ:NXGL) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

NexGel has higher revenue and earnings than Lyra Therapeutics. NexGel is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexGel	$11.42M	0.49	-$3M	-$0.40	N/A
Lyra Therapeutics	$600K	2.18	-$93.43M	-$19.15	N/A

NexGel currently has a consensus target price of $2.00, indicating a potential upside of 225.79%. Given NexGel's stronger consensus rating and higher probable upside, analysts plainly believe NexGel is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexGel	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

NexGel has a net margin of -28.54% compared to Lyra Therapeutics' net margin of -5,491.17%. NexGel's return on equity of -64.29% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NexGel	-28.54%	-64.29%	-29.64%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

2.2% of NexGel shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 20.6% of NexGel shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, NexGel had 8 more articles in the media than Lyra Therapeutics. MarketBeat recorded 8 mentions for NexGel and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 beat NexGel's score of -0.24 indicating that Lyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NexGel	Neutral
Lyra Therapeutics	Neutral

NexGel has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Summary

NexGel beats Lyra Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Lyra Therapeutics compare to Biotricity?

Biotricity (NASDAQ:BTCY) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Biotricity has a net margin of -80.42% compared to Lyra Therapeutics' net margin of -5,491.17%. Biotricity's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

In the previous week, Biotricity had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Biotricity and 0 mentions for Lyra Therapeutics. Biotricity's average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Biotricity	Neutral
Lyra Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Biotricity has higher revenue and earnings than Lyra Therapeutics. Biotricity is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06M	0.38	-$14.09M	-$0.16	N/A
Lyra Therapeutics	$600K	2.18	-$93.43M	-$19.15	N/A

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biotricity has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Summary

Biotricity beats Lyra Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Lyra Therapeutics compare to Zynex?

Lyra Therapeutics (NASDAQ:LYRA) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Zynex has higher revenue and earnings than Lyra Therapeutics. Zynex is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	2.18	-$93.43M	-$19.15	N/A
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A

Zynex has a consensus price target of $4.90, suggesting a potential upside of 3,820.00%. Given Zynex's stronger consensus rating and higher probable upside, analysts plainly believe Zynex is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by company insiders. Comparatively, 49.3% of Zynex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zynex has a net margin of -68.35% compared to Lyra Therapeutics' net margin of -5,491.17%. Zynex's return on equity of -804.30% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Zynex	-68.35%	-804.30%	-36.67%

In the previous week, Zynex had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Zynex and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 equaled Zynex'saverage media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Zynex	Neutral

Lyra Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Zynex has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

Summary

Zynex beats Lyra Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Lyra Therapeutics compare to Sonendo?

Sonendo (NYSE:SONX) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonendo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Sonendo has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Sonendo has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Sonendo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonendo	$44.40M	0.07	-$60.92M	-$71.12	N/A
Lyra Therapeutics	$600K	2.18	-$93.43M	-$19.15	N/A

Sonendo has a net margin of -92.74% compared to Lyra Therapeutics' net margin of -5,491.17%. Sonendo's return on equity of -184.01% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonendo	-92.74%	-184.01%	-68.60%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

In the previous week, Sonendo had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Sonendo and 0 mentions for Lyra Therapeutics. Sonendo's average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Sonendo	Neutral
Lyra Therapeutics	Neutral

28.7% of Sonendo shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 7.9% of Sonendo shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Sonendo beats Lyra Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Lyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYRA vs. The Competition

Export

Metric	Lyra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.31M	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.32%
P/E Ratio	-0.03	17.04	20.79	25.05
Price / Sales	2.18	251.21	531.21	72.69
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	0.08	4.39	9.81	6.83
Net Income	-$93.43M	$74.99M	$3.55B	$335.69M
7 Day Performance	-1.53%	-5.15%	-2.12%	-2.15%
1 Month Performance	-1.01%	-8.25%	-4.14%	-2.47%
1 Year Performance	-84.68%	26.23%	28.34%	27.13%

Lyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYRA Lyra Therapeutics	N/A	$0.74 +13.6%	N/A	-86.2%	$1.31M	$600K	N/A	50	Gap Down
ITOC Itonic	0.2474 of 5 stars	$0.30 -1.0%	N/A	N/A	$5.05M	$520K	N/A	N/A	Gap Down
NXGL NexGel	1.6862 of 5 stars	$0.55 +7.0%	$2.00 +265.6%	-74.3%	$4.84M	$11.27M	N/A	10	Earnings Report Gap Up
BTCY Biotricity	N/A	$0.16 -7.3%	N/A	-65.6%	$4.60M	$12.06M	N/A	40	Gap Up High Trading Volume
ZYXI Zynex	2.1891 of 5 stars	$0.13 flat	$4.90 +3,820.0%	N/A	$3.80M	$108.20M	N/A	770

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYRA) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyra Therapeutics (LYRA) Competitors

LYRA vs. ITOC, NXGL, BTCY, ZYXI, and SONX

How does Lyra Therapeutics compare to Itonic?

Summary

How does Lyra Therapeutics compare to NexGel?

Summary

How does Lyra Therapeutics compare to Biotricity?

Summary

How does Lyra Therapeutics compare to Zynex?

Summary

How does Lyra Therapeutics compare to Sonendo?

Summary

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyra Therapeutics (LYRA) Competitors

LYRA vs. ITOC, NXGL, BTCY, ZYXI, and SONX

How does Lyra Therapeutics compare to Itonic?

Do institutionals and insiders hold more shares of LYRA or ITOC?

Which has better valuation and earnings, LYRA or ITOC?

Is LYRA or ITOC more profitable?

Does the media refer more to LYRA or ITOC?

Do analysts recommend LYRA or ITOC?

Which has more risk & volatility, LYRA or ITOC?

Summary

How does Lyra Therapeutics compare to NexGel?

Which has preferable earnings & valuation, NXGL or LYRA?

Do analysts recommend NXGL or LYRA?

Is NXGL or LYRA more profitable?

Do insiders and institutionals believe in NXGL or LYRA?

Does the media favor NXGL or LYRA?

Which has more volatility & risk, NXGL or LYRA?

Summary

How does Lyra Therapeutics compare to Biotricity?

Is BTCY or LYRA more profitable?

Does the media prefer BTCY or LYRA?

Do analysts rate BTCY or LYRA?

Which has preferable valuation & earnings, BTCY or LYRA?

Do institutionals & insiders have more ownership in BTCY or LYRA?

Which has more risk & volatility, BTCY or LYRA?

Summary

How does Lyra Therapeutics compare to Zynex?

Which has higher valuation and earnings, LYRA or ZYXI?

Do analysts rate LYRA or ZYXI?

Do insiders & institutionals hold more shares of LYRA or ZYXI?

Is LYRA or ZYXI more profitable?

Does the media refer more to LYRA or ZYXI?

Which has more volatility & risk, LYRA or ZYXI?

Summary

How does Lyra Therapeutics compare to Sonendo?

Do analysts rate SONX or LYRA?

Which has more risk and volatility, SONX or LYRA?

Which has better earnings & valuation, SONX or LYRA?

Is SONX or LYRA more profitable?

Does the media favor SONX or LYRA?

Do institutionals and insiders hold more shares of SONX or LYRA?

Summary

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools